{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:06:34Z","timestamp":1763017594123,"version":"3.41.0"},"reference-count":113,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["lipidjournal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.jacl.2015.11.006","type":"journal-article","created":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T04:39:10Z","timestamp":1449031150000},"page":"240-264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["A lipidologist perspective of global lipid guidelines and recommendations, part 2: Lipid treatment goals"],"prefix":"10.1016","volume":"10","author":[{"given":"Harold E.","family":"Bays","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2015.11.006_bib1","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1161\/hc3501.095214","article-title":"Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study","volume":"104","author":"Sharrett","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.11.006_bib2","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.11.006_bib3","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.11.006_bib4","first-page":"CD004816","article-title":"Statins for the primary prevention of cardiovascular disease","volume":"1","author":"Taylor","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacl.2015.11.006_bib5","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.11.006_bib6","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.006_bib7","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.006_bib8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease","volume":"102","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.11.006_bib9","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.11.006_bib10","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","article-title":"Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis","volume":"375","author":"Jun","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.11.006_bib11","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.006_bib12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.006_bib13","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.11.006_bib14","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/MJT.0b013e31815a69fc","article-title":"The \u2018forgotten\u2019 bile acid sequestrants: is now a good time to remember?","volume":"14","author":"Bays","year":"2007","journal-title":"Am J Ther"},{"key":"10.1016\/j.jacl.2015.11.006_bib15","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.006_bib16","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.jacc.2005.05.085","article-title":"Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis","volume":"46","author":"Robinson","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.11.006_bib17","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1515\/hmbci-2013-0048","article-title":"Sex hormones in the cardiovascular system","volume":"18","author":"dos Santos","year":"2014","journal-title":"Horm Mol Biol Clin Investig"},{"key":"10.1016\/j.jacl.2015.11.006_bib18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jsbmb.2013.10.009","article-title":"The Women's Health Initiative trial and related studies: 10 years later: a clinician's view","volume":"142","author":"Gurney","year":"2014","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.jacl.2015.11.006_bib19","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1586\/14779072.3.5.789","article-title":"Torcetrapib\/atorvastatin combination therapy","volume":"3","author":"Bays","year":"2005","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.jacl.2015.11.006_bib20","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/11599310-000000000-00000","article-title":"On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors","volume":"72","author":"Johns","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.jacl.2015.11.006_bib21","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1056\/NEJMoa1405386","article-title":"Inactivating mutations in NPC1L1 and protection from coronary heart disease","volume":"371","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.006_bib22","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/humu.20882","article-title":"Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease","volume":"30","author":"Abifadel","year":"2009","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jacl.2015.11.006_bib23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.mcna.2012.01.009","article-title":"LDL cholesterol: the lower the better","volume":"96","author":"Martin","year":"2012","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.jacl.2015.11.006_bib24","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1749-6632.2012.06478.x","article-title":"Optimal lipid targets for the new era of cardiovascular prevention","volume":"1254","author":"Ramjee","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jacl.2015.11.006_bib25","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.amjcard.2007.03.102","article-title":"Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study)","volume":"100","author":"LaRosa","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2015.11.006_bib26","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jacc.2005.04.064","article-title":"Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy","volume":"46","author":"Wiviott","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.11.006_bib27","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.jacc.2010.09.082","volume":"57","author":"Hsia","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.11.006_bib28","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.006_bib29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.amjcard.2009.02.040","article-title":"Safety and efficacy of achieving very low low-density lipoprotein cholesterol levels with rosuvastatin 40 mg daily (from the ASTEROID Study)","volume":"104","author":"Wiviott","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2015.11.006_bib30","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"year":"2015","series-title":"The Endocrinologic and Metabolic Drugs Advisory Committee Meeting Briefing Document","key":"10.1016\/j.jacl.2015.11.006_bib31"},{"key":"10.1016\/j.jacl.2015.11.006_bib32","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.006_bib33","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.amjcard.2015.02.006","article-title":"Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin\/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia","volume":"115","author":"Ballantyne","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2015.11.006_bib34","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/MOL.0000000000000072","article-title":"Hypobetalipoproteinemia and abetalipoproteinemia","volume":"25","author":"Welty","year":"2014","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2015.11.006_bib35","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.atherosclerosis.2006.08.039","article-title":"The C679X\u00a0mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population","volume":"193","author":"Hooper","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2015.11.006_bib36","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1086\/507488","article-title":"Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote","volume":"79","author":"Zhao","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jacl.2015.11.006_bib37","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/S0140-6736(10)60310-8","article-title":"Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.11.006_bib38","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.006_bib39","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial","volume":"292","author":"de Lemos","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2015.11.006_bib40","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.006_bib41","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2015.11.006_bib42","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.amjcard.2003.09.031","article-title":"Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?","volume":"93","author":"Waters","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2015.11.006_bib43","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/j.amjcard.2013.08.031","article-title":"Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia","volume":"112","author":"Bays","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2015.11.006_bib44","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.amjcard.2011.03.079","article-title":"Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study)","volume":"108","author":"Bays","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2015.11.006_bib45","first-page":"2118","article-title":"Efficacy and safety of combining alirocumab with atorvastatin or rosuvastatin versus statin intensification or adding ezetimibe in high cardiovascular risk patients: ODYSSEY OPTIONS I and II [abstract]","volume":"130","author":"Bays","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.11.006_bib46","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.11.006_bib47","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(06)69472-5","article-title":"Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial","volume":"368","author":"Nakamura","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.11.006_bib48","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2015.11.006_bib49","first-page":"1772","article-title":"Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study","volume":"44","author":"Koren","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.11.006_bib50","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/j.jacc.2014.09.003","article-title":"ACC\/AHA\/AACVPR\/AAFP\/ANA concepts for clinician-patient shared accountability in performance measures: a report of the American College of Cardiology\/American Heart Association Task Force on Performance Measures","volume":"64","author":"Peterson","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.11.006_bib51","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/eurheartj\/ehu107","article-title":"The ACC\/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC\/EAS guidelines for the management of dyslipidaemias 2011","volume":"35","author":"Ray","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2015.11.006_bib52","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.11.006_bib53","unstructured":"Orringer CE. Key Aspects of the NLA Recommendations for the Patient-Centered Management of Dyslipidemia. http:\/\/www.acc.org\/. December 11, 2015. Available at: http:\/\/www.acc.org\/latest-in-cardiology\/articles\/2015\/12\/11\/13\/50\/key-aspects-of-the-nla-recommendations-for-the-patient-centered-management-of-dyslipidemia. Accessed January 8, 2016."},{"key":"10.1016\/j.jacl.2015.11.006_bib54","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","article-title":"National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1\u2014full report","volume":"9","author":"Jacobson","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2015.11.006_bib55","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/jama.2015.10017","article-title":"New therapies in the treatment of high cholesterol: an argument to return to goal-based lipid guidelines","volume":"314","author":"Shrank","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2015.11.006_bib56","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1001\/jama.2012.366","article-title":"Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis","volume":"307","author":"Boekholdt","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2015.11.006_bib57","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1161\/CIRCULATIONAHA.107.713438","article-title":"Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment","volume":"117","author":"Kastelein","year":"2008","journal-title":"Circulation"},{"year":"2014","series-title":"Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. NICE clinical guideline 181","key":"10.1016\/j.jacl.2015.11.006_bib58"},{"year":"2014","series-title":"Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease","key":"10.1016\/j.jacl.2015.11.006_bib59"},{"key":"10.1016\/j.jacl.2015.11.006_bib60","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/01.JCN.0000305061.88624.fc","article-title":"High-dose statin therapy for secondary prevention of stroke: stroke prevention by aggressive reduction in cholesterol levels study review","volume":"23","author":"Schwertz","year":"2008","journal-title":"J Cardiovasc Nurs"},{"key":"10.1016\/j.jacl.2015.11.006_bib61","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1161\/CIRCULATIONAHA.106.654756","article-title":"Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE)","volume":"115","author":"Deedwania","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.11.006_bib62","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1110874","article-title":"Effect of two intensive statin regimens on progression of coronary disease","volume":"365","author":"Nicholls","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.006_bib63","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","article-title":"Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial","volume":"291","author":"Nissen","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2015.11.006_bib64","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jacl.2013.12.005","article-title":"An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia\u2014full report","volume":"8","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2015.11.006_bib65","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.11.006_bib66","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jacc.2006.04.070","article-title":"Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy","volume":"48","author":"Cannon","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.11.006_bib67","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(86)90597-0","article-title":"Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men","volume":"2","author":"Martin","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.11.006_bib68","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.006_bib69","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1056\/NEJMc0707445","article-title":"A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction [letter]","volume":"358","author":"Kathiresan","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.006_bib70","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","article-title":"Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis","volume":"60","author":"Ference","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.11.006_bib71","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.11.006_bib72","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.006_bib73","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.006_bib74","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1161\/CIRCULATIONAHA.105.586347","article-title":"A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22","volume":"113","author":"Wiviott","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.11.006_bib75","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.006_bib76","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.2337\/dc05-2415","article-title":"Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)","volume":"29","author":"Knopp","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacl.2015.11.006_bib77","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstr\u00f6m","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.006_bib78","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.006_bib79","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.006_bib80","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1185\/030079902125000787","article-title":"Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study","volume":"18","author":"Athyros","year":"2002","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jacl.2015.11.006_bib81","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.006_bib82","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.006_bib83","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1001\/jama.287.24.3215","article-title":"Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial","volume":"287","author":"Serruys","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2015.11.006_bib84","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial","volume":"285","author":"Schwartz","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2015.11.006_bib85","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.amjcard.2005.11.031","article-title":"Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese","volume":"97","author":"Sakamoto","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2015.11.006_bib86","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.11.006_bib87","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cjca.2012.11.032","article-title":"2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult","volume":"29","author":"Anderson","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacl.2015.11.006_bib88","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2015.11.006_bib89","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.11.006_bib90","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.11.006_bib91","doi-asserted-by":"crossref","first-page":"850","DOI":"10.5551\/jat.19166","article-title":"Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan\u20142012 version","volume":"20","author":"Teramoto","year":"2013","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jacl.2015.11.006_bib92","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.ahj.2003.10.052","article-title":"Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) trial","volume":"148","author":"Thompson","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2015.11.006_bib93","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1001\/jama.285.4.430","article-title":"Early statin treatment following acute myocardial infarction and 1-year survival","volume":"285","author":"Stenestrand","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2015.11.006_bib94","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.atherosclerosis.2009.12.001","article-title":"Early intensive statin treatment for six months improves long-term clinical outcomes in patients with acute coronary syndrome (Extended-ESTABLISH trial): a follow-up study","volume":"210","author":"Dohi","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2015.11.006_bib95","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1001\/archinte.166.17.1814","article-title":"The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials","volume":"166","author":"Hulten","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacl.2015.11.006_bib96","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000342765","article-title":"Cholesterol issues in Japan\u2014why are the goals of cholesterol levels set so low?","volume":"62","author":"Hamazaki","year":"2013","journal-title":"Ann Nutr Metab"},{"key":"10.1016\/j.jacl.2015.11.006_bib97","doi-asserted-by":"crossref","first-page":"b2376","DOI":"10.1136\/bmj.b2376","article-title":"The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials","volume":"338","author":"Brugts","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.jacl.2015.11.006_bib98","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.jacc.2008.08.039","article-title":"Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients","volume":"52","author":"Mills","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.11.006_bib99","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.11.006_bib100","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.11.006_bib101","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199907083410202","article-title":"Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease","volume":"341","author":"Pitt","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.006_bib102","doi-asserted-by":"crossref","first-page":"969","DOI":"10.7326\/0003-4819-119-10-199311150-00002","article-title":"Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS)","volume":"119","author":"Blankenhorn","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacl.2015.11.006_bib103","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0735-1097(96)00388-9","article-title":"Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease. LDL-Apheresis Atherosclerosis Regression Study (LAARS)","volume":"28","author":"Aengevaeren","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.11.006_bib104","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1056\/NEJM199701163360301","article-title":"The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts","volume":"336","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.006_bib105","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0002-9149(97)00303-2","article-title":"Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg\/dl in patients with hyperlipidemia and coronary artery disease","volume":"80","author":"Brown","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2015.11.006_bib106","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1001\/jama.288.23.2998","article-title":"Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2015.11.006_bib107","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1001\/jama.282.24.2340","article-title":"Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials","volume":"282","author":"LaRosa","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2015.11.006_bib108","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.amjcard.2014.08.009","article-title":"Impact of baseline lipoprotein and C-reactive protein levels on coronary atheroma regression following high-intensity statin therapy","volume":"114","author":"Puri","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2015.11.006_bib109","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jacc.2014.05.056","article-title":"Accuracy of statin assignment using the 2013 AHA\/ACC Cholesterol Guideline versus the 2001 NCEP ATP III guideline: correlation with atherosclerotic plaque imaging","volume":"64","author":"Johnson","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.11.006_bib110","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jacc.2014.06.1186","article-title":"A systematic examination of the 2013 ACC\/AHA pooled cohort risk assessment tool for atherosclerotic cardiovascular disease","volume":"64","author":"Karmali","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.11.006_bib111","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1161\/CIRCOUTCOMES.114.001139","article-title":"Atherosclerotic cardiovascular disease prevention: a comparison between the third Adult Treatment Panel and the new 2013 treatment of blood cholesterol guidelines","volume":"7","author":"Paixao","year":"2014","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacl.2015.11.006_bib112","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1056\/NEJMoa1315665","article-title":"Application of new cholesterol guidelines to a population-based sample","volume":"370","author":"Pencina","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacl.2015.11.006_bib113","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccl.2015.02.001","volume":"33","author":"Adhyaru","year":"2015","journal-title":"Cardiol Clin"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287415004468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287415004468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T16:48:58Z","timestamp":1748710138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287415004468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":113,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S1933287415004468"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2015.11.006","relation":{},"ISSN":["1933-2874"],"issn-type":[{"type":"print","value":"1933-2874"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A lipidologist perspective of global lipid guidelines and recommendations, part 2: Lipid treatment goals","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2015.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 National Lipid Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}